| Leukemia, Myelocytic, Acute
Idhifa vs Xospata
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Idhifa vs Xospata with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXospata has a higher rate of injection site reactions vs Idhifa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xospata but not Idhifa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Idhifa
Xospata
At A Glance
Oral
Daily
IDH2 inhibitor
Oral
Daily
FLT3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
Dosing
Leukemia, Myelocytic, Acute 100 mg orally once daily until disease progression or unacceptable toxicity; treat for a minimum of 6 months in patients without disease progression or unacceptable toxicity to allow time for clinical response.
Leukemia, Myelocytic, Acute 120 mg orally once daily with or without food; in the absence of disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for a clinical response.
Contraindications
—
- Hypersensitivity to gilteritinib or any of the excipients
Adverse Reactions
Most common (>=20%) Nausea, diarrhea, vomiting, decreased appetite, elevated bilirubin
Serious Differentiation syndrome, leukocytosis, tumor lysis syndrome, diarrhea, nausea, vomiting, decreased appetite
Most common (>=10%) transaminase increased, myalgia/arthralgia, fatigue/malaise, fever, mucositis, edema, rash, noninfectious diarrhea, dyspnea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, renal impairment, abdominal pain, neuropathy, insomnia, dysgeusia
Serious differentiation syndrome, posterior reversible encephalopathy syndrome, prolonged QT interval, pancreatitis
Pharmacology
IDH2 inhibitor; enasidenib is a small molecule that selectively targets mutant IDH2 variants (R140Q, R172S, R172K), decreasing 2-hydroxyglutarate (2-HG) levels and inducing myeloid differentiation in IDH2-mutated AML.
Gilteritinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including FLT3; it inhibits FLT3 receptor signaling and proliferation in cells expressing FLT3-ITD and FLT3 tyrosine kinase domain mutations, and induces apoptosis in leukemic cells expressing FLT3-ITD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Idhifa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Xospata
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (3/12) · Qty limit (12/12)
UnitedHealthcare
Idhifa
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Xospata
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Idhifa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xospata
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IdhifaView full Idhifa profile
XospataView full Xospata profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.